Qizheng Tibetan Medicine is leading a national key special project to support research on major neurological diseases using Tibetan medicine.

　　On January 19, the kickoff meeting for the 2019 National Key Research and Development Program—"Demonstration Development Study on the Treatment of Baimai Disease, a Major Tibetan Medical Condition, Using the Classic Tibetan Medicines Ruyi Zhenbao Tablets and Baimai Ointment"—was held in Beijing. The project is led by Gansu Qizheng Tibetan Medicine Co., Ltd., a wholly-owned subsidiary of Qizheng Tibetan Medicine (002287), and involves the joint participation of leading research institutions including the Tibet Autonomous Region Tibetan Hospital, Tibet University of Tibetan Medicine, China Academy of Chinese Medical Sciences, Xuanwu Hospital of Capital Medical University, and Central South University for Nationalities. This project will focus on target indications such as acute ischemic stroke (AIS), which represents central nervous system injury, and diabetic peripheral neuropathy (DPN), a type of peripheral nerve injury, and will explore comprehensive clinical treatment approaches from traditional Tibetan medicines to leverage their therapeutic advantages.

　　It is understood that this research project is the only one under the 2019 National Key R&D Program of the Ministry of Science and Technology—specifically, the “Modernization Research on Traditional Chinese Medicine”—that focuses on developing drugs for the prevention and treatment of major diseases centered around classic ethnic medicines. It also marks the first time that a collaborative effort among medical institutions, industry, academia, and research organizations, integrating Tibetan, Chinese, and Western medicine, has been undertaken to explore solutions for major neurological disorders by tapping into the unique therapeutic advantages of Tibetan medicine. The purpose of this meeting is to invite the heads of various sub-projects and relevant expert leaders to thoroughly communicate about the objectives of each sub-project, implementation plans, and inter-group collaboration, reaching a consensus to ensure the smooth execution of the project.

　　The project is divided into five research groups, covering the following areas: basic theoretical studies on the classic Tibetan medicine Ruyi Zhenbao Tablets and Bai Mai Ointment formulations and their related diseases; modern pharmacological studies on Ruyi Zhenbao Tablets and Bai Mai Ointment; metabolic and toxicological studies on Ruyi Zhenbao Tablets and Bai Mai Ointment; establishment of a comprehensive quality standard system for the entire production chain of Ruyi Zhenbao Tablets and Bai Mai Ointment; and clinical studies on the treatment of acute ischemic stroke and diabetic peripheral neuropathy using Ruyi Zhenbao Tablets and Bai Mai Ointment.

　　Upon completion of the project’s research, a comprehensive management platform and technical evaluation system will be established, integrating Tibetan medicine formula combinations, mechanisms of action, pharmacological and toxicological profiles, quality enhancement, and clinical studies. This will enable end-to-end drug research across the entire chain, filling gaps in clinical treatment while comprehensively improving the quality of Tibetan medicines and providing a model for the subsequent development of other Tibetan medicinal products.

　　Bai Mai disease is a term used in Tibetan medicine that can be loosely understood as neurological disorders, such as stroke and peripheral neuritis. Bai Mai disease is common in high-altitude regions. Over the long-term struggle against this illness, Tibetan physicians have accumulated extensive clinical experience, making Bai Mai disease one of the key strengths of Tibetan medicine.

　　A wealth of clinical practice has demonstrated that the traditional internal and external therapeutic approaches of Tibetan medicine are highly effective in treating white-pulse disease and have been clinically applied for thousands of years. However, due to significant differences between Tibetan and Western medicine in terms of evidence-based methodologies, insufficient basic research on the mechanisms of action of Tibetan medicines, and a lack of modern studies supporting the necessity of combined drug therapies, the rational and standardized promotion and application of classic Tibetan medicinal treatments and distinctive therapeutic techniques nationwide have been greatly hampered. Therefore, conducting research centered on white-pulse disease is highly necessary.

　　According to the introduction, this project highlights pharmaceutical studies, mechanistic research, safety evaluations, and evidence-based research guided by Tibetan medical theory. It adopts a technological approach that integrates Tibetan and Western medicine. While emphasizing the inheritance, exploration, and innovation of classic Tibetan medical theories related to the "white pulse disease," it also makes full use of modern technologies to conduct basic and clinical research on selected traditional Tibetan medicines for both oral and topical treatments of this condition—particularly focusing on clinical application and evidence-based research. In addition, while taking into account the sustainable study of core medicinal resources, the project focuses on tackling key technical challenges in the industry, such as particle size control in Tibetan medicinal ointments and sterilization of oral formulations, thereby establishing a comprehensive, multi-level technical evaluation system spanning the entire chain.

　　It is foreseeable that, as the project takes shape and various institutions work closely together, a comprehensive technical research system and a high-level R&D platform will be established—integrating multidisciplinary expertise from medicine, industry, education, and research, as well as leveraging the strengths of leading domestic institutions—to create a fully integrated industrial chain for Tibetan medicine. This will also foster a comprehensive research base for the modern development of Tibetan medicine. Through systematic studies encompassing formulation theory, clinical application guidelines, optimization of preparation processes, refinement of draft quality standards, and rigorous evaluation of safety and efficacy, this initiative will set a benchmark for Tibetan medicine research.

　　Reporting media: Securities Times

　　Report link: http://company.stcn.com/2020/0119/15607206.shtml